Monte Rosa Therapeutics (GLUE) Equity Ratio (2023 - 2025)
Historic Equity Ratio for Monte Rosa Therapeutics (GLUE) over the last 3 years, with Q3 2025 value amounting to 0.53.
- Monte Rosa Therapeutics' Equity Ratio fell 1801.4% to 0.53 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.53, marking a year-over-year decrease of 1801.4%. This contributed to the annual value of 0.51 for FY2024, which is 1389.17% down from last year.
- According to the latest figures from Q3 2025, Monte Rosa Therapeutics' Equity Ratio is 0.53, which was down 1801.4% from 0.75 recorded in Q2 2025.
- In the past 5 years, Monte Rosa Therapeutics' Equity Ratio ranged from a high of 0.79 in Q1 2023 and a low of 0.51 during Q4 2024
- Over the past 3 years, Monte Rosa Therapeutics' median Equity Ratio value was 0.65 (recorded in 2024), while the average stood at 0.66.
- As far as peak fluctuations go, Monte Rosa Therapeutics' Equity Ratio crashed by 2750.27% in 2024, and later surged by 2239.03% in 2025.
- Monte Rosa Therapeutics' Equity Ratio (Quarter) stood at 0.59 in 2023, then dropped by 13.89% to 0.51 in 2024, then grew by 5.21% to 0.53 in 2025.
- Its Equity Ratio stands at 0.53 for Q3 2025, versus 0.75 for Q2 2025 and 0.7 for Q1 2025.